pS2 protein: A marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients

British Journal of Cancer

Volumn 74, Issue 7, 1996, Pages 1120-1125

  Soubeyran, I ^a   Quenel N ^a   Coindre, J M ^a,b   Bonichon, F ^a   Durand, M ^a   Wafflart, J ^a   Mauriac, L ^a  

^a INSTITUT BERGONIÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Breast neoplasm; Oestrogen receptor; Progesterone receptor; pS2; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE; PROGESTERONE RECEPTOR; PROTEIN; TAMOXIFEN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST DUCT; CANCER GRADING; CANCER HORMONE THERAPY; CANCER REGRESSION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; POSTMENOPAUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; TUMOR VOLUME;

EID: 0029784957     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.500     Document Type: Article

References (41)

1. AKHTAR SS, ALLAN, SG, RODGER A, CHETTY UDI, SMYTH JH AND LEONARD RCF. (1991). A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients. Eur. J. Surg. Oncol., 17, 30-35.
2. BERGMAN L, VAN DONGEN JA, VAN OOIJEN B AND VAN LEEUWEN FE. (1995). Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease? Breast Cancer Res. Treat., 34, 77-83.
3. BRADBEER JW AND KYNGON J. (1983). Primary treatment of breast cancer in elderly women with tamoxifen. Clin. Oncol., 9, 31-34.
4. COOMBES RC, POWLES TJ, BERGER L, WILSON P, MCCLELLAND RA, GAZET JC, TROTT PA AND FORD HT. (1987). Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet, 2, 701-703.
5. DAVIES N, MOIR G, CARPENTER R, CUTHBERT A, HERBERT A, ROYLE GT AND TAYLOR I. (1991). Erica predicts response to tamoxifen in elderly women with breast cancer. Ann. R. Coll. Surg. Engl., 73, 361-363.
6. DORION-BONNET F, QUENEL N, COINDRE JM, MAURIAC L, BONICHON F, DURAND M, WAFFLARD J, MOSCOW JA, COWAN KH AND GUALDE N. (1993). Expression of the GSTζ gene and response to tamoxifen therapy in locally advanced breast carcinomas. Ann. NY Acad. Sci., 698, 182-185.
7. FOUDRAINE NA, VERHOEF LCG AND BURGHOUTS JTM. (1992). Tamoxifen as sole therapy for primary breast cancer in the elderly patient. Eur. J. Cancer, 28A, 900-903.
8. FRIGO B, PILOTTI S, ZURRIDA S, ERMELLINO L, MANZARI A AND RILKE F. (1995). Analysis of estrogen and progesterone receptors on preoperative fine-needle aspirates. Breast Cancer Res. Treat., 33, 179-184.
9. GASKELL DJ, HAWKINS RA, SANGSTERL K, CHETTY U AND FORREST APM. (1989). Relation between immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen. Lancet, 1, 1044-1046.
10. GASKELL DJ, HAWKINS RA, DE CARTERET S, CHETTY U, SANGSTERL K AND FORRIEST APM. (1992). Indications for primary tamoxifen therapy in elderly women with breast cancer. Br. J. Surg., 79, 1317-1320.
11. GAZET JC, MARKOPOULOS CH, FORD HT, COOMBES RC, BLAND JM AND DIXON RC. (1988). Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet, 1, 679-681.
12. GILBERT L, ELWOOD LJ, MERINO M, MASOOD S, BARNES R, STEINBERG SM, LAZAROUS DF, PIERCH L, D'ANGELO T, MOSCOW JA, TOWNSEND AJ AND COWAN KH. (1993). A pilot study of Pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J. Clin. Oncol., 11, 49-58.
13. HENRY JA, NICHOLSON S, HENNESY C, LENNARD TWJ, MAY FEB AND WESTLEY BR. (1989). Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy. Br. J. Cancer, 61, 32-38.
14. HENRY JA, PIGGOTT NH, MALLICK UK, NICHOLSON S, FARNDON JR, WESTLEY BR AND MAY FEB. (1991). pNR-2 pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br. J. Cancer, 63, 615-622.
15. HILL C. (1993). Prognostic value of continuous variable and optimal cutoff point. Bull. Cancer, 80, 649-652.
16. HOROBIN JM, PREECE PE, DEWAR JA, WOOD RAB AND CUSCHIERI A. (1991). Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br. J. Surg., 78, 213-217.
17. HURLIMANN J, GEBHARD S AND GOMEZ F. (1993). Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology, 23, 239-248.
18. KATZ RI., PATEL S, SNEIGE N, FRITSCHE JR, HORTOBAGYI GN, AMES FC. BROOKS T AND ORDONEZ NG. (1990). Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas. Breast Cancer Res. Treat., 15, 191-203.
19. KLIJN JGM, BERNS EMJJ AND FOEKENS JA. (1993). Prognostic factors and response to therapy in breast cancer. Cancer Surv., 18, 165-198.
20. LUQMANI YA, RICKETTS D, RYALL G, TURNBULL L, LAW M AND COOMBES RC. (1993). Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor. Int. J. Cancer, 54, 619-623.
21. MCCARTY KS JR, MILLER LS, COX EB, KONRATH J AND MCCARTY KS SR. (1985). Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med., 109, 716-721.
22. MCCLELLAND RA, BERGER U, MILLER LS, POWLES TJ AND COOMBES RC. (1986). Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J. Clin. Oncol., 4, 1171-1176.
23. DE MASCAREL I, SOUBEYRAN I, MACGROGAN G, WAFFLART J, BONICHON F, DURAND M, AVRIL A, MAURIAC L, TROJANI M AND COINDRE JM. (1995). Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas: concordance with biochemical assay and prognostic significance. App. Immunohistochem., 3, 222-231.
24. MASIAKOWSKI P, BREATHNACH R, BLOCK J, GANNON R, KRUST A AND CHAMBON P. (1982). Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res., 10, 7895-7903.
25. MAURIAC L, WAFFLART J, DURAND M, PARSI B, DE MASCAREL I, TROJANI M AND MEUGE-MORAW C. (1981). Contribution of drill-biopsies to pre-treatment investigation of breast adenocarcinomas. Bull. Cancer, 68, 417-421.
26. MAURIAC L, DURAND M, CHAUVERGNE J, DAVID M AND WAFFLART J. (1989). Locally advanced breast cancer: survival prognosis for tumors with estrogen and progesterone receptors. Bull. Cancer, 76, 33-41.
27. NICHOLSON RI, MCCLELLAND RA, FINLAY P, EATON CL, GULLICK WJ, DIXON AR, ROBERTSON JFR, ELLIS IO AND BLAMEY RW. (1993). Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur. J. Cancer, 29A, 1018-1023.
28. PERTSCHUK LP, EISENBERG KB, CARTER AC AND FELDMAN JG. (1985). Immunohistologic localization of estrogen receptors in breast cancer wtih monoclonal antibodies. Correlation with biochemistry and clinical endocrine response. Cancer, 55, 1513-1518.
29. PERTSCHUK LP, KIM DS, NAYER K, FELDMAN JG, EISENBERG KB, CARTER AC, RONG ZT, THELMO WL, FLEISHER J AND GREENE GL. (1990). Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic and biochemical correlations and relationship to endocrine response and survival. Cancer, 66, 1663-1670.
30. QUENEL N, COINDRE JM, WAFFLART J, BONICHON F, DE MASCAREL I, TROJANI M, DURAND M AND AVRIL A. (1995). The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res. Treat., 35, 283-291.
31. RAVDIN PM, GREEN S, DORR TM, MCGUIRE WL, FABIAN C, PUGH RP, CARTER RD, RIVKIN SE, BORST JR, BELT RJ, METCH BAND OSBORNE CK. (1992). Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J. Clin. Oncol., 10, 1284-1291.
32. RILKE F, COLNAGHI MI, CASCINELLI N, ANDREOLA S, BALDINI MT, BUFALINO R, DELLA PORTA G, MENARD S, PIEROTTI MA AND TESTORI A. (1991). Prognostic significance of HER-2 NEU expression in breast cancer and its relationship to other prognostic factors. Int. J. Cancer, 49, 44-49.
33. ROBERTSON JFR, ELLIS IO, ELSTON CW AND BLAMEY RW. (1992a). Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur. J. Cancer, 28A, 908-910.
34. ROBERTSON JFR, BATES K, PEARSON D, BLAMEY RW AND NICHOLSON RL (1992b). Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br.J. Cancer, 65, 727-730.
35. SCHWARTZ LH, KOERNER FC, EDGERTON SM, SAWICKA JM, RIO MC, BELLOCQ JP, CHAMBON P AND THOR AD. (1991). pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res., 51, 624-628.
36. SIMON R AND ALTMAN DG. (1994). Statistical aspects of prognostic-factor studies in oncolgoy. Br. J. Cancer, 69, 979-985.
37. SOUBEYRAN I, WAFFLART J, BONICHON F, DE MASCAREL I, TROJANI M, DURAND M, AVRIL A AND COINDRE JM. (1995). Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res. Treat., 34, 119-128.
38. SOUBEYRAN I, QUENEL N, MAURIAC L, DURAND M, BONICHON F AND COINDRE JM. (1996). Variation of hormonal receptor. pS2, c-erbB2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases. Br. J. Cancer, 73, 735-743.
39. WILLIAMS MR, GILSON D, MARSH L, MORGAN DAL, NICHOLSON RI, ELSTON CW, GRIFFITHS K AND BLAMEY RW. (1988). The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer. Eur. J. Surg. Oncol., 14, 235-240.
40. WILSON YG, RHODES M, IBRAHIM NBN, PADFIELD CJH AND CAWTHORN SJ. (1994). Immunocytochemical staining of pS2 protein in fine-needle aspirate from breast cancer is an accurate guide to response to tamoxifen in patients aged over 70 years. Br. J. Surg., 81, 1155-1158.
41. WRIGHT C, NICHOLSON S, ANGUS B, SAINSBURY JRC, FARNDON J, CAIRNS J, HARRIS AL AND HORNE CHW. (1992). Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer, 65, 118-121.